Cruz-Bañares A, Diver C

Language: Spanish
References: 27
Page: 178-186
PDF size: 84.31 Kb.

ABSTRACT

Background: Fibromyalgia is a complex condition primarily characterized by widespread pain and fatigue; its complexity makes its diagnosis and multidisciplinary treatment difficult. This is commonly associated with poor knowledge amongst health care professionals. Objective: To assess the specific knowledge about fibromyalgia and its non-pharmacological treatment among Mexican physiotherapists. Methods and Materials: a cross-sectional study of Mexican physiotherapists was conducted utilizing a quantitative questionnaire to assess their knowledge about Fibromyalgia symptoms, diagnosis and treatment. Results: The sample included 97/405 registered physiotherapists. 73% of responding participants had previous experience treating patients with Fibromyalgia; diffuse pain (90%) and restless sleep (78%), were identified as the main symptoms. The most common method of diagnosis was consultation including physical examination by a medical Practitioner (73%); physical exercise and antidepressants were considered the optimum treatment combination (73%). 81% expressed that physical activity can improve patient well-being. More than half of the participants (55%) were unfamiliar with the national Mexican clinical guideline, and 69% were unfamiliar with any national or international guidelines. Conclusions: The knowledge of fibromyalgia among Mexican physiotherapists is inconsistent with current best practice guidelines. Education of physiotherapists regarding awareness and utilization of clinical guidelines could improve management of patients with Fibromyalgia.

REFERENCES

1. Chinn S, Caldwell W, Gritsenko K. FibromyalgiaPathogenesis and Treatment Options Update.Curr Pain Headache Rep. 2016;20(4):25.

2. Queiroz LP. Worldwide epidemiology offibromyalgia. Curr Pain Headache Rep.2013;17(8):356.

3. Clark P. Frecuencias y características de lafibromialgia en el Hospital General de México:revisión de la Epidemiología. Rev Mex Reumatol2001;16:191-7.

4. Bidari A, Ghavidel Parsa B, Ghalehbaghi B.Challenges in fibromyalgia diagnosis: frommeaning of symptoms to fibromyalgia labeling.Korean J Pain. 2018;31(3):147-54.

5. Sumpton JE, Moulin DE. Fibromyalgia. HandbClin Neurol. 2014;119:513-27.

6. Wolfe F, Clauw DJ, Fitzcharles MA, GoldenbergDL, Katz RS, Mease P, et al. The AmericanCollege of Rheumatology preliminary diagnosticcriteria for fibromyalgia and measurement ofsymptom severity. Arthritis Care Res (Hoboken).2010;62(5):600-10.

7. Wolfe F, Clauw DJ, Fitzcharles MA, GoldenbergDL, Häuser W, Katz RL, et al. 2016 Revisions tothe 2010/2011 fibromyalgia diagnostic criteria.Semin Arthritis Rheum. 2016;46(3):319-29.

8. Abeles M, Solitar BM, Pillinger MH, Abeles AM.Update on fibromyalgia therapy. Am J Med.2008;121(7):555-61.

9. Walitt B, Klose P, Fitzcharles MA, Phillips T,Häuser W. Cannabinoids for fibromyalgia.Cochrane Database Syst Rev.2016;7:CD011694.

10. Macfarlane GJ, Kronisch C, Dean LE, Atzeni F,Häuser W, Fluß E, et al. EULAR revisedrecommendations for the management offibromyalgia. Ann Rheum Dis. 2017;76(2):318-28.

11. Pronovost PJ. Enhancing physicians' use ofclinical guidelines. JAMA. 2013;310(23):2501-2.

12. Guerrero Montenegro VJ, López Roldan V,Mejía Holguín Y, Parrilla Ortiz JI, Perez Rojas A,Ramos Garzón E, et al. Guía de Practica Clínica.Diagnóstico Y Tratamiento de Fibromialgia en eladulto. In: Salud Sd, editor. Mexico, DF:CENETEC; 2009.

13. Acuña Ortiz FE, Capitán de la Cruz VA, LeónJiménez FE. Knowledge on fibromyalgia amonggeneral practitioners, from Chiclayo-Peru, 2016.Reumatol Clin. 2017;13(6):326-30.

14. Kaki AM, Hazazi AA. Assessment of medicalpractitioners' knowledge of fibromyalgia in SaudiArabia. Saudi J Anaesth. 2018;12(2):178-82.

15. Gómez IJQ, Ortiz AS, Barrientos JR. Frecuenciade la fibromialgia primaria, secundaria ypatologías asociadas, en el Servicio de Medicinade Rehabilitación del Hospital Regional 1 deOctubre del ISSSTE. Rev Mex Med Fis Rehab.2009;21:49-55.

16. Colmenares-Roa T, Huerta-Sil G, Infante-Castañeda C, Lino-Pérez L, Alvarez-HernándezE, Peláez-Ballestas I. Doctor-PatientRelationship Between Individuals WithFibromyalgia and Rheumatologists in Public andPrivate Health Care in Mexico. Qual Health Res.2016;26(12):1674-88.

17. Perrot S, Choy E, Petersel D, Ginovker A,Kramer E. Survey of physician experiences andperceptions about the diagnosis and treatment offibromyalgia. BMC Health Serv Res.2012;12:356.

18. Suda AL, Jennings F, Bueno VC, Natour J.Development and validation of FibromyalgiaKnowledge Questionnaire: FKQ. Rheumatol Int.2012;32(3):655-62.

19. International statistical classification of diseaseand related problems. ICD-10 [Internet]. 1992.

20. Kamoun S, Elleuch M, Le Lay K, Feki H, TaiebC, André E, et al. [Evaluation of knowledge offibromyalgia in Tunisia]. Tunis Med.2010;88(10):703-6.

21. Arnold LM, Clauw DJ. Challenges ofimplementing fibromyalgia treatment guidelinesin current clinical practice. Postgrad Med.2017;129(7):709-14.

22. Barth JH, Misra S, Aakre KM, Langlois MR,Watine J, Twomey PJ, et al. Why are clinicalpractice guidelines not followed? Clin Chem LabMed. 2016;54(7):1133-9.

23. Murad MH, Asi N, Alsawas M, Alahdab F. Newevidence pyramid. Evid Based Med.2016;21(4):125-7.

24. Moretti FA, Heymann RE, Marvulle V, Pollak DF,Riera R. Assessing knowledge on fibromyalgiaamong Internet users. Rev Bras Reumatol.2011;51(1):7-19.

25. Thorne SE, Harris SR, Mahoney K, Con A,McGuinness L. The context of health carecommunication in chronic illness. Patient EducCouns. 2004;54(3):299-306.

26. Liu PH, Landrum MB, Weeks JC, Huskamp HA,Kahn KL, He Y, et al. Physicians' propensity todiscuss prognosis is associated with patients'awareness of prognosis for metastatic cancers.J Palliat Med. 2014;17(6):673-82.

27. Francke AL, Smit MC, de Veer AJ, Mistiaen P.Factors influencing the implementation of clinicalguidelines for health care professionals: asystematic meta-review. BMC Med Inform DecisMak. 2008;8:38.